Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-d9dc9ab79b2a856f92a3151fb8d4fca9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9"/>
<resource>
<Composition>
<id value="composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9</b></p><a name="composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9"> </a><a name="hccomposition-en-d9dc9ab79b2a856f92a3151fb8d4fca9"> </a><a name="composition-en-d9dc9ab79b2a856f92a3151fb8d4fca9-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1342/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - erleada</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1342/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpd9dc9ab79b2a856f92a3151fb8d4fca9"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - erleada"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Erleada is and what it is used for</li><li>What you need to know before you take Erleada</li><li>How to take Erleada</li><li>Possible side effects</li><li>How to store Erleada</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What erleada is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What erleada is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Erleada is Erleada is a cancer medicine that contains the active substance apalutamide . What Erleada is used for It is used to treat adult men with prostate cancer that:</p><p>has metastasised to other parts of the body and still responds to medical or surgical treatments that lower testosterone (also called hormone-sensitive prostate cancer).</p><p>has not metastasised to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone (also called castration-resistant prostate cancer). How Erleada works Erleada works by blocking the activity of hormones called androgens (such as testosterone). Androgens can cause the cancer to grow. By blocking the effect of androgens, apalutamide stops prostate cancer cells from growing and dividing.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take erleada"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take erleada"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Erleada</p><p>if you are allergic to apalutamide or any of the other ingredients of this medicine (listed in section 6).</p><p>if you are a woman who is pregnant or may become pregnant (see the Pregnancy and contraception section below for more information). Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine. Warnings and precautions Talk to your doctor or pharmacist before taking this medicine if:</p><p>you have ever had fits or seizures.</p><p>you are taking any medicines to prevent blood clots (such as warfarin, acenocoumarol).</p><p>you have any heart or blood vessel conditions, including heart rhythm problems (arrhythmia).</p><p>you have ever had a widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS) or a severe skin rash or skin peeling, blistering and/or mouth sores (Stevens-Johnson syndrome/toxic epidermal necrolysis or SJS/TEN) after taking Erleada or other related medicines. If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine. Falls and broken bones Falls have been observed in patients taking Erleada. Take extra care to reduce your risk of a fall. Broken bones have been observed in patients taking this medicine. Heart disease, stroke, or mini-stroke Blockage of the arteries in the heart or in part of the brain that can lead to death has happened in some people during treatment with Erleada. Your healthcare provider will monitor you for signs and symptoms of heart or brain problems during your treatment with this medicine. Call your healthcare provider or go to the nearest emergency room right away if you get:</p><p>chest pain or discomfort at rest or with activity, or</p><p>shortness of breath, or</p><p>muscle weakness/paralysis in any part of the body, or</p><p>difficulty in speaking. If you are taking any medicines, talk to your doctor or pharmacist to see if they are associated with an increased risk of seizure, bleeding or heart condition. Severe Cutaneous Adverse Reactions (SCARs) Severe Cutaneous Adverse Reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS) or Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), have been reported with the use of Erleada. DRESS can appear as widespread rash, high body temperature and enlarged lymph nodes. SJS/TEN can appear initially as reddish target-like spots or circular patches often with central blisters on the trunk. Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu-like symptoms. The rashes may progress to widespread peeling of the skin and life-threatening complications or be fatal. If you develop a serious rash or another of these skin symptoms, stop taking this medicine and contact your doctor or seek medical attention immediately. If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine. See section 4 Serious side effects at the top of section 4 for more information. Interstitial Lung Disease Cases of interstitial lung disease (non-infectious inflammation within the lungs that may lead to permanent damage) have been observed in patients taking Erleada, including fatal cases. The symptoms of interstitial lung disease are cough and shortness of breath sometimes with fever which are not caused by physical activity. Seek immediate medical attention, if you experience symptoms that may be signs of interstitial lung disease. Children and adolescents This medicine is not for use in children and adolescents under 18 years of age. If a child or young person accidentally takes this medicine:</p><p>go to the hospital straight away</p><p>take this package leaflet with you to show to the emergency doctor. Other medicines and Erleada Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Erleada can affect the way some other medicines work. Also, some other medicines can affect the way Erleada works. In particular, tell your doctor if you are taking medicines that:</p><p>lower high fat levels in the blood (such as gemfibrozil)</p><p>treat bacterial infections (such as moxifloxacin, clarithromycin)</p><p>treat fungal infections (such as itraconazole, ketoconazole)</p><p>treat HIV infection (such as ritonavir, efavirenz, darunavir)</p><p>treat anxiety (such as midazolam, diazepam)</p><p>treat epilepsy (such as phenytoin, valproic acid)</p><p>treat gastroesophageal reflux disease (conditions where there is too much acid in the stomach) (such as omeprazole)</p><p>prevent blood clots (such as warfarin, clopidogrel, dabigatran etexilate)</p><p>treat hayfever and allergies (such as fexofenadine)</p><p>lower cholesterol levels (such as statins such as rosuvastatin, simvastatin)</p><p>treat heart conditions or lower blood pressure (such as digoxin, felodipine)</p><p>treat heart rhythm problems (such as quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</p><p>treat thyroid conditions (such as levothyroxine)</p><p>treat gout (such as colchicine)</p><p>lower blood glucose (such as repaglinide)</p><p>treat cancer (such as lapatinib, methotrexate)</p><p>treat opioid addiction or pain (such as methadone)</p><p>treat serious mental illnesses (such as haloperidol) You need to list the names of the medicines you take and show the list to your doctor or pharmacist when you start a new medicine. Mention to your doctor that you are taking Erleada if the doctor wants to start you on any new medicine. The dose of Erleada or any other medicines that you are taking may need to be changed. Pregnancy and contraception information for men and women Information for women</p><p>Erleada must not be taken by women who are pregnant, may become pregnant, or who are breast-feeding. This medicine may harm your unborn baby. Information for men follow this advice during treatment and for 3 months after stopping</p><p>If you are having sex with a pregnant woman use a condom to protect the unborn baby.</p><p>If you are having sex with a woman who can become pregnant - use a condom and another highly effective method of contraception. Use contraception during treatment and for 3 months after stopping. Talk to your doctor if you have any questions about contraception. This medicine may reduce male fertility. Driving and using machines Erleada is not likely to affect you being able to drive and use any tools or machines. The side effects for this medicine include seizures. If you are at higher risk of seizures (see section 2 Warnings and precautions ), talk to your doctor. Erleada contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 240 mg dose (4 tablets), that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take erleada"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take erleada"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor may also prescribe other medicines while you are taking Erleada. How much to take The recommended dose of this medicine is 240 mg (four 60 mg tablets) once a day. Taking Erleada</p><p>Take this medicine by mouth.</p><p>You can take this medicine with food or between meals.</p><p>Swallow each tablet whole to make sure your full dose is taken. Do not crush or split the tablets. If you take more Erleada than you should If you take more than you should, stop taking this medicine and contact your doctor. You may have an increased risk of side effects. If you forget to take Erleada</p><p>If you forget to take this medicine, take your usual dose as soon as you remember on the same day.</p><p>If you forget to take this medicine for the whole day - take your usual dose the following day.</p><p>If you forget to take this medicine for more than one day - talk to your doctor straight away.</p><p>Do not take a double dose to make up for a forgotten dose. If you stop taking Erleada Do not stop taking this medicine without checking with your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Stop taking Erleada and seek medical attention immediately if you notice any of the following symptoms:</p><p>widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS)</p><p>reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis). Tell your doctor straight away if you notice any of the following serious side effects your doctor may stop treatment: Very common: may affect more than 1 in 10 people</p><p>falls or fractures (broken bones). Your healthcare provider may monitor you more closely if you are at risk for fractures. Common: may affect up to 1 in 10 people</p><p>heart disease, stroke, or mini-stroke. Your healthcare provider will monitor you for signs and symptoms of heart or brain problems during your treatment. Call your healthcare provider or go to the nearest emergency room right away if you get chest pain or discomfort at rest or with activity, or shortness of breath, or if you get muscle weakness/paralysis in any part of the body, or difficulty in speaking during your treatment with Erleada. Uncommon: may affect up to 1 in 100 people</p><p>fit or seizure. Your healthcare provider will stop this medicine if you have a seizure during treatment.</p><p>restless legs syndrome (urges to move the legs to stop painful or odd sensations, often occurring at night). Not known: frequency cannot be estimated from the available data</p><p>coughing and shortness of breath, possibly accompanied by fever, that is not brought on by physical activity (inflammation within the lungs, known as interstitial lung disease). Tell your healthcare provider right away if you notice any of the serious side effects above. Side effects include Tell your healthcare provider if you notice any of the following side effects: Very common (may affect more than 1 in 10 people):</p><p>feeling very tired</p><p>joint pain</p><p>skin rash</p><p>decreased appetite</p><p>high blood pressure</p><p>hot flush</p><p>diarrhoea</p><p>broken bones</p><p>falls</p><p>weight loss. Common (may affect up to 1 in 10 people):</p><p>muscle spasms</p><p>itching</p><p>hair loss</p><p>change in sense of taste</p><p>blood test showing high level of cholesterol in the blood</p><p>blood test showing high level of a type of fat called triglycerides in the blood</p><p>heart disease</p><p>stroke or mini-stroke caused by low blood flow to part of the brain</p><p>under-active thyroid which can make you feel more tired and have difficulty getting started in the morning, and blood tests may also show an under-active thyroid. Uncommon (may affect up to 1 in 100 people):</p><p>seizures/fits. Not known (frequency cannot be estimated from the available data):</p><p>abnormal heart tracing on an ECG (electrocardiogram)</p><p>widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS)</p><p>reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, which can be preceded by fever and flu-like symptoms. These serious skin rashes can be potentially life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis). Tell your healthcare provider if you notice any of the side effects listed above. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store erleada"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store erleada"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the container (blister foils, inner wallet, outer wallet, bottle, and carton) after EXP. The expiry date refers to the last day of that month. Store in the original package in order to protect from moisture. This medicine does not require any special temperature storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Erleada contains</p><p>The active substance is apalutamide. Each film-coated tablet contains 60 mg of apalutamide.</p><p>The other ingredients of the tablet core are colloidal anhydrous silica, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicified microcrystalline cellulose. The film-coating contains iron oxide black (E172), iron oxide yellow (E172), macrogol, polyvinyl alcohol (partially hydrolysed), talc, and titanium dioxide (E171) (see Section 2, Erleada contains sodium). What Erleada looks like and contents of the pack Erleada film-coated tablets are slightly yellowish to greyish green, oblong-shaped, film-coated tablets (17 mm long x 9 mm wide), with AR 60 written on one side. The tablets may be supplied either in a bottle or in a wallet pack. Not all pack sizes may be marketed. Bottle The tablets are supplied in a plastic bottle with a child-resistant closure. Each bottle contains 120 tablets and a total of 6 g of desiccant. Each carton contains one bottle. Store in the original package. Do not swallow or discard desiccant. 28-day carton Each 28-day carton contains 112 film-coated tablets in 4 cardboard wallet packs of 28 film-coated tablets each. 30-day carton Each 30-day carton contains 120 film-coated tablets in 5 cardboard wallet packs of 24 film-coated tablets each. Marketing Authorisation Holder Janssen-Cilag International NV Turnhoutseweg B-2340 Beerse Belgium Manufacturer Janssen Cilag SpA Via C. Janssen Borgo San Michele Latina 04100, Italy For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Janssen-Cilag NV Tel/T l: +32 14 64 94 <a href="mailto:janssen@jacbe.jnj.com">janssen@jacbe.jnj.com</a> Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 <a href="mailto:lt@its.jnj.com">lt@its.jnj.com</a></p><p>&<br/>.: +359 2 489 94 <a href="mailto:jjsafety@its.jnj.com">jjsafety@its.jnj.com</a> Luxembourg/Luxemburg Janssen-Cilag NV T l/Tel: +32 14 64 94 <a href="mailto:janssen@jacbe.jnj.com">janssen@jacbe.jnj.com</a> esk republika Janssen-Cilag s.r.o. Tel: +420 227 012 Magyarorsz g Janssen-Cilag Kft. Tel.: +36 1 884 <a href="mailto:2janssenhu@its.jnj.com">2janssenhu@its.jnj.com</a> Danmark Janssen-Cilag A/S Tlf: +45 4594 <a href="mailto:8jacdk@its.jnj.com">8jacdk@its.jnj.com</a> Malta AM MANGION LTD Tel: +356 2397 6Deutschland Janssen-Cilag GmbH Tel: +49 2137 955 <a href="mailto:jancil@its.jnj.com">jancil@its.jnj.com</a> Nederland Janssen-Cilag B.V. Tel: +31 76 711 <a href="mailto:1janssen@jacnl.jnj.com">1janssen@jacnl.jnj.com</a> Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 <a href="mailto:7ee@its.jnj.com">7ee@its.jnj.com</a> Norge Janssen-Cilag AS Tlf: +47 24 12 65 <a href="mailto:jacno@its.jnj.com">jacno@its.jnj.com</a></p><p>Janssen-Cilag . . . . T : +30 210 80 90 sterreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 Espa a Janssen-Cilag, S.A. Tel: +34 91 722 81 <a href="mailto:contacto@its.jnj.com">contacto@its.jnj.com</a> Polska Janssen-Cilag Polska Sp. z o.o. Tel.: +48 22 237 60 France Janssen-Cilag T l: 0 800 25 50 75 / +33 1 55 00 40 <a href="mailto:medisource@its.jnj.com">medisource@its.jnj.com</a> Portugal Janssen-Cilag Farmac utica, Lda. Tel: +351 214 368 Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 <a href="mailto:jjsafety@JNJCR.JNJ.com">jjsafety@JNJCR.JNJ.com</a> Rom nia Johnson & Johnson Rom nia SRL Tel: +40 21 207 1Ireland Janssen Sciences Ireland UC Tel: 1 800 709 <a href="mailto:medinfo@its.jnj.com">medinfo@its.jnj.com</a> Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 <a href="mailto:Janssen_safety_slo@its.jnj.com">Janssen_safety_slo@its.jnj.com</a> sland Janssen-Cilag AB c/o Vistor hf. S mi: +354 535 <a href="mailto:7janssen@vistor.is">7janssen@vistor.is</a> Slovensk republika Johnson & Johnson, s.r.o. Tel: +421 232 408 Italia Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 <a href="mailto:janssenita@its.jnj.com">janssenita@its.jnj.com</a> Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 <a href="mailto:jacfi@its.jnj.com">jacfi@its.jnj.com</a></p><p>: +357 22 207 Sverige Janssen-Cilag AB Tfn: +46 8 626 50 <a href="mailto:jacse@its.jnj.com">jacse@its.jnj.com</a> Latvija UAB "JOHNSON & JOHNSON" fili le Latvij Tel: +371 678 <a href="mailto:93lv@its.jnj.com">93lv@its.jnj.com</a> United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Tel: +44 1 494 567 <a href="mailto:medinfo@its.jnj.com">medinfo@its.jnj.com</a> This leaflet was last revised in. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpd9dc9ab79b2a856f92a3151fb8d4fca9"/>
<resource>
<MedicinalProductDefinition>
<id value="mpd9dc9ab79b2a856f92a3151fb8d4fca9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpd9dc9ab79b2a856f92a3151fb8d4fca9"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpd9dc9ab79b2a856f92a3151fb8d4fca9</b></p><a name="mpd9dc9ab79b2a856f92a3151fb8d4fca9"> </a><a name="hcmpd9dc9ab79b2a856f92a3151fb8d4fca9"> </a><a name="mpd9dc9ab79b2a856f92a3151fb8d4fca9-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1342/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Erleada 60 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1342/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Erleada 60 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
